Abstract:CD47, a cell surface glycoprotein, plays an important role in modulating neutrophil (PMN) migration across endothelial and epithelial monolayers. Here we show that anti-CD47 monoclonal antibodies (mAbs) delay PMN migration across collagen-coated filters or T84 epithelial monolayers toward the chemoattractant formylmethionylleucylphenylalanine (fMLP). Despite delayed transmigration by anti-CD47 mAbs, the numbers of PMN migrating across in either condition were the same as in the presence of control non-inhibitory mAbs. Cell surface labeling and immunoprecipitation demonstrated upregulation of CD47 to the PMN cell surface with kinetics similar to those of the transmigration response. Subcellular fractionation studies revealed redistribution of CD47 from intracellular compartments that co-sediment with secondary granules to plasma membrane-containing fractions after fMLP stimulation. Experiments performed to investigate potential signaling pathways revealed that inhibition of tyrosine phosphorylation with genistein reversed the anti-CD47-mediated PMN migration delay, whereas inhibition of phosphatidylinositol 3-kinase only partially reversed anti-CD47 effects that correlated with a rapid increase in PMN cell surface CD47. Analysis of the contribution of epithelial-expressed CD47 to PMN transmigration revealed that PMN migration across CD47-deficient epithelial monolayers (CaCO2) was significantly increased after stable transfection with CD47. These results suggest that cell surface CD47 and downstream tyrosine phosphorylation signaling events regulate, in part, the rate of PMN migration during the inflammatory response. CD47, a cell surface glycoprotein, plays an important role in modulating neutrophil (PMN) migration across endothelial and epithelial monolayers. Here we show that anti-CD47 monoclonal antibodies (mAbs) delay PMN migration across collagen-coated filters or T84 epithelial monolayers toward the chemoattractant formylmethionylleucylphenylalanine (fMLP). Despite delayed transmigration by anti-CD47 mAbs, the numbers of PMN migrating across in either condition were the same as in the presence of control non-inhibitory mAbs. Cell surface labeling and immunoprecipitation demonstrated upregulation of CD47 to the PMN cell surface with kinetics similar to those of the transmigration response. Subcellular fractionation studies revealed redistribution of CD47 from intracellular compartments that co-sediment with secondary granules to plasma membrane-containing fractions after fMLP stimulation. Experiments performed to investigate potential signaling pathways revealed that inhibition of tyrosine phosphorylation with genistein reversed the anti-CD47-mediated PMN migration delay, whereas inhibition of phosphatidylinositol 3-kinase only partially reversed anti-CD47 effects that correlated with a rapid increase in PMN cell surface CD47. Analysis of the contribution of epithelial-expressed CD47 to PMN transmigration revealed that PMN migration across CD47-deficient epithelial monolayers (CaCO2) was significantly increased after stable transfection with CD47. These results suggest that cell surface CD47 and downstream tyrosine phosphorylation signaling events regulate, in part, the rate of PMN migration during the inflammatory response. polymorphonuclear leukocyte immunoglobulin variable domain myeloperoxidase Hanks' balanced salt buffer devoid of Ca2+ and Mg2+ formylmethionylleucylphenylalanine phosphatidylinositol 3-kinase monoclonal antibody Dulbecco's modified Eagle's medium junction adhesion molecule thrombospondin-1 fluorescence-activated cell sorting protein kinase C mitogen-activated protein kinase/extracellular signal-regulated kinase kinase fluorescein isothiocyanate polymerase chain reaction alkaline phosphatase In many inflammatory conditions, large numbers of PMN1migrate across vascular endothelium, cell matrix, and mucosal surfaces in response to chemotactic signals. Under these conditions, PMN release active oxygen species, proteolytic enzymes, and inflammatory mediators that result in tissue injury. Thus, it is intuitive that large scale PMN migration and accumulation in tissues correlates with disease activity and patient symptoms (1Stockley R.A. Am. J. Med. 1995; 99: 8S-13SAbstract Full Text PDF PubMed Scopus (47) Google Scholar,2Kumar N.B. Nostrant T.T. Appelman H.D. Am. J. Surg. Pathol. 1982; 6: 523-529Crossref PubMed Scopus (142) Google Scholar). The process of PMN movement from the vasculature, through the interstitial matrix, and across mucosal surfaces requires sequential interactions between neutrophil surface molecules and counter-receptors present on tissues or cell surfaces (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar, 4Lawrence M.B. Springer T.A. Cell. 1991; 65: 859-873Abstract Full Text PDF PubMed Scopus (1887) Google Scholar, 5Muller W.A. Weigl S.A. Deng X. Phillips D.M. J. Exp. Med. 1993; 178: 449-460Crossref PubMed Scopus (990) Google Scholar, 6Spertini O. Kansas G.S. Munro J.M. Griffin J.D. Tedder T.F. Nature. 1991; 349: 691-694Crossref PubMed Scopus (235) Google Scholar). Previous studies have shown that the leukocyte β2 integrin CD11bCD18 is essential in this process, especially in early interactions with epithelial and endothelial cells during the transmigration response (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar,7Diamond M.S. Alon R. Parkos C.A. Quinn M.T. Springer T.A. J. Cell Biol. 1995; 130: 1473-1482Crossref PubMed Scopus (255) Google Scholar, 8von Andrian U.H. Chambers J.D. McEvoy L.M. Bargatze R.F. Arfors K.E. Butcher E.C. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 7538-7542Crossref PubMed Scopus (901) Google Scholar). Although PMN migration across endothelial monolayers is only partially blocked by anti-CD11bCD18 antibodies, there is near complete inhibition of PMN migration across epithelial monolayers by the same antibodies (9Parkos C.A. Delp C. Arnaout M.A. Madara J.L. J. Clin. Invest. 1991; 88: 1605-1612Crossref PubMed Scopus (292) Google Scholar). The importance of β2 integrins in PMN transmigration is manifested clinically by patients with leukocyte adhesion deficiency who lack β2 integrins, resulting in a failure of PMN to migrate out of the vasculature and leaving high levels of circulating PMN (10Anderson D.C. Schmalstieg F.C. Arnaout M.A. Kohl S. Tosi M.F. Dana N. Buffone G.J. Hughes B.J. Brinkley B.R. Dickey W.D. et al.J. Clin. Invest. 1984; 74: 536-551Crossref PubMed Scopus (159) Google Scholar, 11Dana N. Todd R.F. d. Pitt J. Springer T.A. Arnaout M.A. J. Clin. Investig. 1984; 73: 153-159Crossref PubMed Scopus (111) Google Scholar). A second protein that has been shown to play an important role in PMN transmigration is CD47 (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). PMN migration across both epithelial and endothelial monolayers can be inhibited by anti-CD47 antibodies (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar, 12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar, 13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar). CD47 was originally defined as a tumor-specific marker for ovarian carcinoma but is now known to be widely expressed on all hematopoietic cells and most other cell types (14Mawby W.J. Holmes C.H. Anstee D.J. Spring F.A. Tanner M.J. Biochem. J. 1994; 304: 525-530Crossref PubMed Scopus (114) Google Scholar, 15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar, 16Reinhold M.I. Lindberg F.P. Plas D. Reynolds S. Peters M.G. Brown E.J. J. Cell Sci. 1995; 108: 3419-3425Crossref PubMed Google Scholar). The primary structure of human and mouse CD47 predicts the protein containing an N-terminal extracellular IgV domain, a membrane-spanning domain with multiple transmembrane α helices, and an intracellular loop (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar). In addition to regulating PMN transmigration, other studies have implicated CD47 in multiple cellular functions. In particular, antibodies to CD47 have been shown to interfere with αvβ3-mediated cell functions (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar), as well as to block endothelial Ca2+ influxes during adhesion to fibronectin- or vitronectin-coated surfaces (17Schwartz M.A. Brown E.J. Fazeli B. J. Biol. Chem. 1993; 268: 19931-19934Abstract Full Text PDF PubMed Google Scholar). CD47 has been shown to bind to the C terminus of thrombospondin-1 (18Gao A.G. Lindberg F.P. Finn M.B. Blystone S.D. Brown E.J. Frazier W.A. J. Biol. Chem. 1996; 271: 21-24Abstract Full Text Full Text PDF PubMed Scopus (332) Google Scholar), therefore suggesting a role in platelet activation. Anti-CD47 antibodies have also been used to implicate CD47 in T cell activation (19Waclavicek M. Majdic O. Stulnig T. Berger M. Baumruker T. Knapp W. Pickl W.F. J. Immunol. 1997; 159: 5345-5354PubMed Google Scholar, 20Reinhold M.I. Lindberg F.P. Kersh G.J. Allen P.M. Brown E.J. J. Exp. Med. 1997; 185: 1-11Crossref PubMed Scopus (140) Google Scholar), T and B cell apoptosis (21Pettersen R.D. Hestdal K. Olafsen M.K. Lie S.O. Lindberg F.P. J. Immunol. 1999; 162: 7031-7040PubMed Google Scholar, 22Mateo V. Lagneaux L. Bron D. Biron G. Armant M. Delespesse G. Sarfati M. Nat. Med. 1999; 5: 1277-1284Crossref PubMed Scopus (198) Google Scholar), and stroma-supported erythropoiesis (23Furusawa T. Yanai N. Hara T. Miyajima A. Obinata M. J. Biochem. 1998; 123: 101-106Crossref PubMed Scopus (23) Google Scholar). Recently, CD47 has been shown to bind to P84 (also termed SIRPα, Bit, SHPS-1, and MFR) (24Jiang P. Lagenaur C.F. Narayanan V. J. Biol. Chem. 1999; 274: 559-562Abstract Full Text Full Text PDF PubMed Scopus (275) Google Scholar, 25Seiffert M. Cant C. Chen Z. Rappold I. Brugger W. Kanz L. Brown E.J. Ullrich A. Buhring H.J. Blood. 1999; 94: 3633-3643Crossref PubMed Google Scholar, 26Vernon-Wilson E.F. Kee W.J. Willis A.C. Barclay A.N. Simmons D.L. Brown M.H. Eur. J. Immunol. 2000; 30: 2130-2137PubMed Google Scholar), and this interaction has been broadly implicated in the regulation of memory formation, macrophage multinucleation, B cell aggregation, and red blood cell self-recognition in mice (27Babic I. Schallhorn A. Lindberg F.P. Jirik F.R. J. Immunol. 2000; 164: 3652-3658Crossref PubMed Scopus (47) Google Scholar, 28Oldenborg P.A. Zheleznyak A. Fang Y.F. Lagenaur C.F. Gresham H.D. Lindberg F.P. Science. 2000; 288: 2051-2054Crossref PubMed Scopus (1313) Google Scholar). Despite the diverse array of functional studies on CD47, the biochemical/molecular mechanism(s) of CD47 function remain undefined. Although we have previously observed anti-CD47 antibody-mediated inhibition of PMN transmigration (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar), the molecular basis of this effect is not clear. The objective of the current study was to investigate the mechanism of CD47 function in PMN migration across epithelial cell monolayers and collagen-coated filters. Using a time-course transmigration assay, we demonstrate that fMLP-driven PMN migration across epithelial monolayers and collagen-coated filters is significantly delayed after cell surface CD47 is blocked by functionally inhibitory anti-CD47 mAbs. However, despite delayed transmigration caused by anti-CD47 mAbs, the number of PMN that eventually migrate is the same as that observed with isotype-matched binding controls. Cell surface labeling and immunoprecipitation experiments demonstrate increased CD47 on the PMN cell surface after stimulation with fMLP and after transmigration. PMN subcellular fractionation experiments revealed that increased cell surface CD47 is derived from intracellular membranes that co-sediment with the secondary (specific) granules. Experiments performed to investigate potential signaling pathways revealed that inhibition of PI3K partially reversed anti-CD47 mediated inhibition of migration while also directly enhancing the rate of PMN migration in a fashion that paralleled a rapid increase of PMN cell surface CD47. Additional inhibitor studies revealed that tyrosine phosphorylation inhibition by genistein reversed anti-CD47 effect in a near complete fashion. In further support of the notion that cell surface CD47 positively regulates the rate of migration, we found that transfection of CD47 into deficient epithelial cells (CaCO2) results in enhanced PMN transepithelial migration. Taken together, these results suggest that translocation of CD47 to the cell surface and tyrosine kinase-mediated signaling events are key components that determine the rate of PMN migration in an inflammatory response. T84 cells (passages 60–80) were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium supplemented with 15 mm HEPES buffer (pH 7.5), 14 mm NaHCO3, 40 µg/ml penicillin, 8 µg/ml ampicillin, 90 µg/ml streptomycin, and 6% newborn calf serum. Cells were subcultured or harvested every 6–8 days with 0.1% trypsin and 1.0 mm EDTA in Ca2+ and Mg2+-free phosphate-buffered saline. For transmigration experiments, T84 cells were grown on collagen-coated, permeable polycarbonate filters (5-µm pore size) with a surface area of 0.33 cm2 (Costar, Cambridge, MA) as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). CaCO2 cells were cultured in DMEM supplemented with 10% fetal bovine serum. Transfected CaCO2 cells (CaCO2-pCB6 and CaCO2-CD47) were maintained in the same medium containing 1 mg/ml G418. PMN were isolated from whole blood of normal human volunteers as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Isolated PMN were resuspended in modified Hanks' balanced salt solution devoid of calcium or magnesium (HBSS(−)) (4 °C) at a concentration of 5 × 107 cells/ml and used within 4 h of isolation. C5D5, a functionally inhibitory mAb (IgG1) was produced in our laboratory as previously reported (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). B6H12.2, another functionally inhibitory anti-CD47 mAb (IgG1) (13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar) was purified from supernatants of hybridoma cells obtained from the American Tissue Culture Co. CD47 mAbs PF2.1, PF3.1, and PF10.2 were produced in our laboratory by immunizing female balb/C mice with CD47 immunopurified from 50 g of human spleen cells using previously described methods (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Splenocytes from immunized mice were fused with P3U1 myeloma cells and cultured in selection media containing DBA-2 feeder thymocytes. Hybridoma supernatants were screened for reactivity with purified CD47 by enzyme-linked immunosorbent assay in concert with cell surface staining by immunofluorescence and flow cytometry on T84 epithelial cells and PMN. Hybridomas were then subcloned by limiting dilution, weaned from selection media, and injected into the peritoneal cavities of balb/C mice for ascites fluid production. Antibodies were purified using protein-A-Sepharose affinity chromatography and dialyzed against 150 mm NaCl, 10 mm HEPES, pH 7.4. Monoclonal antibody PF3.1 was coupled to CNBr-activated Sepharose at 2–3 mg/ml described by the manufacturer (Amersham Pharmacia Biotech) and used for immunoprecipitation of CD47. A polyclonal antibody (R12989) was also produced by immunizing rabbits with synthetic peptide SNQKTIQPPRNN, corresponding to a region of the putative C terminus of CD47 (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar). As a non-inhibitory binding control, mAb J3F.1 (mouse IgG1) reactive with human junction adhesion molecule (JAM) was used (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar). Similar to CD47, JAM is a transmembrane IgV superfamily member expressed on the surfaces of both PMN and epithelial cells (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar). As a positive functionally inhibitory control, anti-CD11b mAb CBMR1/29, was used (30Balsam L.B. Liang T.W. Parkos C.A. J. Immunol. 1998; 160: 5058-5065PubMed Google Scholar). Anti-β3 integrin mAbs 15, 33, 27, and LIBs-1 were kind gifts from Dr. Mark Ginsberg. LM609 was kindly provided by Dr. David Cherish. An additional anti-β3 mAb AP1 was purchased from GTI Inc. A functionally blocking mAb to β1 integrin, mAb 13, was kindly provided by Dr. Kenneth Yamada. Purified human thrombospondin-1 (TS1) and anti-TS1 polyclonal antibody R1 were kindly provided by Dr. Jack Lawler (31Sipes J.M. Krutzsch H.C. Lawler J. Roberts D.D. J. Biol. Chem. 1999; 274: 22755-22762Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar). Rabbit polyclonal antibody against human CD11b R7928A was raised by immunizing rabbit with a peptide (DMMSEGGPPGAEPQ) corresponding to the C terminus of CD11b. Peptide 4N1K (KRFYVVMWKK) corresponding to the C-terminal cell binding domain of thrombospondin, which has previously been shown to bind to CD47-transfected cells (18Gao A.G. Lindberg F.P. Finn M.B. Blystone S.D. Brown E.J. Frazier W.A. J. Biol. Chem. 1996; 271: 21-24Abstract Full Text Full Text PDF PubMed Scopus (332) Google Scholar, 32Wang X.Q. Frazier W.A. Mol. Biol. Cell. 1998; 9: 865-874Crossref PubMed Scopus (140) Google Scholar), was synthesized and high performance liquid chromatography-purified to >90% by the Emory Microchemical Facility. PMN transepithelial migration experiments were performed using epithelial monolayers as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Briefly, confluent T84 or CaCO2 monolayers were washed twice with HBSS (20 °C). PMN (1 × 106) in 150 µl of HBSS with or without antibody was added to the upper chamber of the monolayer setup. Transmigration was initiated by adding 1 ml of 1 µm fMLP (in HBSS) into the lower chamber followed by incubation at 37 °C. PMN migration across monolayers into the fMLP-containing lower chambers was quantified by myeloperoxidase (MPO) assay as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). To assay the time course of PMN transmigration, the upper chambers of Transwell devices containing PMN and monolayers were gently moved to new wells containing 1 ml of 1 µm fMLP in 24-well plates at every 30 min as depicted in Fig. 1. PMN migration into the lower chambers at the different time periods was then analyzed by MPO assay. To assay the PMN associated with epithelial monolayers, transmigration was stopped at different time points, and monolayers were washed with HBSS and lysed with 0.5% Triton X-100. Monolayer lysates were then assayed for myeloperoxidase. Apical to basolateral PMN transepithelial migration was performed similarly except that twice as many PMN (2 × 106) were added onto the upper chamber. Additional transmigration experiments were performed using collagen-coated filters devoid of epithelial cells. For these experiments, 20 µl of a PMN suspension containing 1 × 106 cells was stimulated to transmigrate from the upper chamber to the lower chamber containing 0.1 µm fMLP. A number of signal transduction pathway inhibitors were tested for the ability to reverse the effects of anti-CD47 mAbs on PMN transmigration. For these experiments, PMN were pre-treated for 15–60 min with the following agents prior to use in transfilter migration assays: 50–100 nm wortmannin or 20–100 µm LY294002 (PI3K inhibitor (Sigma Chemical Co.)), 0.5 µm straurosporine (PKC and other kinases inhibitor (Biomol)), 10–200 µg/ml genistein (tyrosine phosphorylation inhibitor) and its analog daidzein (both from Biomol), 0.1 µm AG126 (tyrosine phosphorylation inhibitor (Biomol)), 40 µm PP1 (Src family tyrosine kinase inhibitor (Biomol)), 20 µm SB203580 (mitogen-activated protein kinase inhibitor (Biomol)), 20 µm PD-98059 (MEK inhibitor (Biomol)), 10 µmU73122 (phospholipase C inhibitor (Biomol)), 1 mm propranolol (phospholipase D inhibitor (Biomol)), 1 µm GF109203X (PKC inhibitor (Biomol)), 20 µm AG490 (Jak kinase inhibitor (Biomol)), 20 µm H-8 (PKA/G inhibitor (Biomol)), 10 µm H-89 (PKA inhibitor (Biomol)), etc. Control migration was done in the presence of the same dilution of vehicle (Me2SO) in HBSS. For G-protein pathway inhibition experiments, PMN were pre-treated with 200–2000 ng/ml pertussis toxin (Calbiochem) for 2 h at 37 °C before use in migration assays. Surface CD47 labeling was performed by incubation of 100 µl of non-permeabilized PMN (5 × 106 cells) with anti-CD47 mAb C5D5 (20 µg/ml) for 1 h at 4 °C in HBSS after blocking nonspecific binding with 0.5% bovine serum albumin. After washing, PMN were incubated with FITC-conjugated goat anti-mouse secondary antibody (1:200 dilution in HBSS) (PharMingen) for 30 min at 4 °C followed by wash before flow cytometric analysis. CD47 labeling in this condition was compared to that obtained with normal mouse IgG1. To assay PMN surface CD47 expression during transmigration, PMN that remained in the upper chambers or had migrated into the lower chambers of Transwell setups were cooled on ice after various migration time periods followed by antibody labeling and flow cytometry. Cell surface CD47 on PMN was also assessed after PMN were stimulated with fMLP. In these experiments, 5 × 106 PMN in 2 ml of HBSS were allowed to settle in 24-well or 6-well non-tissue culture plates at room temperature for 5 min. fMLP was then added (50 nm) followed by incubation at 37 °C for various time periods. Cells were then chilled on ice and labeling performed as above. PMN (1.5 × 107/ml), in suspension or adherent to 6-well plates, were stimulated with fMLP followed by cell surface biotinylation with 0.5 mg of sulfo-NHS-Biotin (Pierce) in 1 ml of HBSS for 1 h on ice. Excess free Biotin was washed off and quenched with 100 mmNH4Cl. Cells were then solubilized with lysis buffer containing 150 mm NaCl, 2 mmCaCl2, 2 mm Mg Cl2, 1% Triton, 2 µg/ml aprotinin, 1 mm phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, and 1 µg/ml pepstatin. Cell lysates (200–400 µg of total protein) were precleared with control IgG before incubation with 10 µl of PF3.1-Sepharose (conjugated at 2 mg of antibody/ml of Sepharose) for 3 h (4 °C). Washed immunoprecipitates were boiled in 100 µl of sample buffer and subjected to SDS-polyacrylamide gel electrophoresis followed by transfer to nitrocellulose. Nonspecific binding was blocked by 5% nonfat dry milk in TTBS (50 mm Tris. HCl, 200 nm NaCl, 0.05% Tween 20, pH 7.4). Biotin-labeled cell surface CD47 was detected with streptavidin-peroxidase followed by enhanced chemiluminescence (ECL (Amersham Pharmacia Biotech)). Total CD47 was detected by blotting with polyclonal rabbit anti-CD47 antibody R12989 (1:200) and was visualized with peroxidase-conjugated goat anti-rabbit secondary and ECL. Freshly isolated, unstimulated, and fMLP-stimulated PMN (2 × 108/per condition) were resuspended in 5 ml of nitrogen cavitation buffer (0.34m sucrose, 10 mm Hepes, 1 mm EDTA, 0.1 mm MgCl2, 1 mmNa2ATP, pH 7.4) followed by lysis by nitrogen cavitation (15 min, 400 p.s.i.) (4 °C). The lysates were centrifuged (1000 × g) and supernatants were then subjected to isopycnic sucrose density gradient fractionation on linear 20–55% sucrose gradients in a Beckman SW-28 swinging bucket rotor (100,000 × g; 3 h, 4 °C) exactly as previously described (33Parkos C.A. Cochrane C.G. Schmitt M. Jesaitis A.J. J. Biol. Chem. 1985; 260: 6541-6547Abstract Full Text PDF PubMed Google Scholar). 1.5-ml fractions were collected from each gradient and analyzed for sucrose density, protein, plasma membrane (alkaline phosphatase), primary granules (myeloperoxidase), and secondary granules (lactoferrin) as previously described (33Parkos C.A. Cochrane C.G. Schmitt M. Jesaitis A.J. J. Biol. Chem. 1985; 260: 6541-6547Abstract Full Text PDF PubMed Google Scholar). The entire protein coding region of CD47 was PCR-amplified from reverse-transcribed human colonic cDNA with primers C3 (sense) (5′-atgataagcttcctgcatgtggcccctggtagcg) and C6 (antisense) (5′-agcttctagactactctccaaatcggagtccat) located at the 5′-untranslated repeat and 3′-untranslated repeat, respectively. Amplified PCR product was digested with HindIII/XbaI and cloned into pCB6, which had been predigested with the same restriction endonucleases. CaCO2 cells were transfected with pCB6-CD47 or pCB6 (control transfection) using Lipofectin reagent as described by the manufacturer (Life Technologies, Inc.). Stable transfectants were selected by culturing in DMEM containing 1.2 mg/ml Geneticin (Life Technologies, Inc.). Cell surface expression of CD47 was confirmed by immunofluorescence labeling and FACS analysis. The putative extracellular domain of human CD47, including the signal peptide, was PCR-amplified by primers C3(5′-atgataagcttcctgcatgtggcccctggtagcgg) and C4 (5′-ttgattagatctatttggagaaaaccatga) from reverse-transcribed T84 cDNA. The DNA fragment was cloned into the mammalian expression vector AP-tag2 (34Cheng H.J. Flanagan J.G. Cell. 1994; 79: 157-168Abstract Full Text PDF PubMed Scopus (328) Google Scholar), which contains the catalytic domain of human placental alkaline phosphatase (AP) at the C terminus, throughBglII and HindIII restriction sites. After transformation, at least three independent clones were isolated and the entire protein-coding region was confirmed by DNA sequencing. Transient transfections of COS-7 were performed using a standard DEAE-dextran method (35Liu Y. The Mechanism of GAG Autoproteolytic Activation and Enzyme Catalysis.Ph.D. dissertation. University of South Alabama, Mobile, AL1997Google Scholar). Protein expression and secretion was monitored by assaying AP activity in cell culture medium (34Cheng H.J. Flanagan J.G. Cell. 1994; 79: 157-168Abstract Full Text PDF PubMed Scopus (328) Google Scholar). Expressed CD47-AP fusion protein in medium was affinity-purified by PF3.1-Sepharose and eluted with 10 mm TEA/HCl buffer containing 100 mmNaCl, pH 10.5, followed by neutralization, concentration, and dialysis. Previously, we demonstrated that anti-CD47 mAb C5D5 inhibited PMN migration across T84 monolayers (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). However, we noticed that the efficiency of inhibition by C5D5 or another anti-CD47 antibody, B6H12.2 (13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar), was variable in the standard transmigration assays typically consisting of a single time point (normally 2 h). We surmised that the variable inhibition observed might be the result of differences in PMN motility after CD47 inhibition. To address this and further investigate the mechanism of CD47-mediated migration, we modified the in vitro transepithelial migration assay in which PMN migration was assessed at several time points (Fig. 1). Using this assay setup, we tested the effect of inhibitory anti-CD47 mAbs C5D5 and B6H12.2 on the time course of PMN migration across T84 monolayers. As controls, parallel experiments were performed with binding, non-inhibitory isotype-matched anti-JAM mAb J3F.1 (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar) and an inhibitory control antibody reactive with CD11b CD18 (CBRM1/29 (30Balsam L.B. Liang T.W. Parkos C.A. J. Immunol. 1998; 160: 5058-5065PubMed Google Scholar)). As shown in Fig. 2A, in the presence of control non-inhibitory mAbs, less than 10% of the total applied PMN migrated across T84 monolayers during the first 30 min (5.8 ± 0.6% for no antibody and 6.1 ± 2.0% for J3F.1). Massive PMN migration across T84 monolayers occurred during the next 30-min period (2nd 30′) with ∼40% of the applied PMN migrating into the lower chambers (43.6 ± 3.7% for no antibody and 38.7 ± 4.4% for J3F.1). In the third 30-min period (3rd 30′), PMN migration into the lower chamber decreased to 14.6 ± 2.9% for no antibody and 16.8 ± 5.2% for J3F.1. In subsequent time periods, PMN migration across the monolayers continued to decrease to <10% in the fourth 30 min and to <5% in the fifth and sixth 30-min periods, respectively. From Fig. 2 A, total migration of PMN into the lower chamber can be plotted as a function of migration time, which is shown in Fig. 2 B. As can be seen, under non-in

Abstract:CXCL12 (SDF-1α) and CXCR4 are critical for embryonic development and cellular migration in adults. These proteins are involved in HIV-1 infection, cancer metastasis, and WHIM disease. Sequestration and presentation of CXCL12 to CXCR4 by glycosaminoglycans (GAGs) is proposed to be important for receptor activation. Mutagenesis has identified CXCL12 residues that bind to heparin. However, the molecular details of this interaction have not yet been determined. Here we demonstrate that soluble heparin and heparan sulfate negatively affect CXCL12-mediated in vitro chemotaxis. We also show that a cluster of basic residues in the dimer interface is required for chemotaxis and is a target for inhibition by heparin. We present structural evidence for binding of an unsaturated heparin disaccharide to CXCL12 attained through solution NMR spectroscopy and x-ray crystallography. Increasing concentrations of the disaccharide altered the two-dimensional 1H-15N-HSQC spectra of CXCL12, which identified two clusters of residues. One cluster corresponds to β-strands in the dimer interface. The second includes the amino-terminal loop and the α-helix. In the x-ray structure two unsaturated disaccharides are present. One is in the dimer interface with direct contacts between residues His25, Lys27, and Arg41 of CXCL12 and the heparin disaccharide. The second disaccharide contacts Ala20, Arg21, Asn30, and Lys64. This is the first x-ray structure of a CXC class chemokine in complex with glycosaminoglycans. Based on the observation of two heparin binding sites, we propose a mechanism in which GAGs bind around CXCL12 dimers as they sequester and present CXCL12 to CXCR4. CXCL12 (SDF-1α) and CXCR4 are critical for embryonic development and cellular migration in adults. These proteins are involved in HIV-1 infection, cancer metastasis, and WHIM disease. Sequestration and presentation of CXCL12 to CXCR4 by glycosaminoglycans (GAGs) is proposed to be important for receptor activation. Mutagenesis has identified CXCL12 residues that bind to heparin. However, the molecular details of this interaction have not yet been determined. Here we demonstrate that soluble heparin and heparan sulfate negatively affect CXCL12-mediated in vitro chemotaxis. We also show that a cluster of basic residues in the dimer interface is required for chemotaxis and is a target for inhibition by heparin. We present structural evidence for binding of an unsaturated heparin disaccharide to CXCL12 attained through solution NMR spectroscopy and x-ray crystallography. Increasing concentrations of the disaccharide altered the two-dimensional 1H-15N-HSQC spectra of CXCL12, which identified two clusters of residues. One cluster corresponds to β-strands in the dimer interface. The second includes the amino-terminal loop and the α-helix. In the x-ray structure two unsaturated disaccharides are present. One is in the dimer interface with direct contacts between residues His25, Lys27, and Arg41 of CXCL12 and the heparin disaccharide. The second disaccharide contacts Ala20, Arg21, Asn30, and Lys64. This is the first x-ray structure of a CXC class chemokine in complex with glycosaminoglycans. Based on the observation of two heparin binding sites, we propose a mechanism in which GAGs bind around CXCL12 dimers as they sequester and present CXCL12 to CXCR4. Chemokines are a superfamily of 8-11-kDa secreted chemotactic cytokines, which are modulated by glycosaminoglycans (GAGs), 3The abbreviations used are: GAG, glycosaminoglycan; HEK-293, human embryonic kidney 293; HSQC, heteronuclear single quantum coherence. 3The abbreviations used are: GAG, glycosaminoglycan; HEK-293, human embryonic kidney 293; HSQC, heteronuclear single quantum coherence. activate chemokine receptors, and direct cellular migration (1Fernandez E.J. Lolis E. Annu. Rev. Pharmacol. Toxicol. 2002; 42: 469-499Crossref PubMed Scopus (494) Google Scholar). The 43 known human chemokines are divided into two major and two minor families. All have a three-dimensional structure composed of a three-stranded β-sheet followed by an α-helix, which is stabilized by conserved cysteine residues forming typically two disulfide bonds (Fig. 1A) (2Lapidot T. Petit I. Exp. Hematol. 2002; 30: 973-981Abstract Full Text Full Text PDF PubMed Scopus (691) Google Scholar). The chemokine CXCL12 (CXCL12) is the sole physiological agonist for CXCR4 (3Bleul C.C. Farzan M. Choe H. Parolin C. Clark-Lewis I. Sodroski J. Springer T.A. Nature. 1996; 382: 829-833Crossref PubMed Scopus (1743) Google Scholar). CXCL12 has been observed as a dimer in several crystal structures (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar, 5Ohnishi Y. Senda T. Nandhagopal N. Sugimoto K. Shioda T. Nagal Y. Mitsui Y. J. Interferon Cytokine Res. 2000; 20: 691-700Crossref PubMed Scopus (45) Google Scholar). However, it has been reported as both a monomer and as a dimer in solution (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar, 7Holmes W.D. Consler T.G. Dallas W.S. Rocque W.J. Willard D.H. Protein Expr. Purif. 2001; 21: 367-377Crossref PubMed Scopus (37) Google Scholar). The oligomeric state is modulated by pH, concentration, and the presence of divalent cations and heparin (8Veldkamp C.T. Peterson F.C. Pelzek A.J. Volkman B.F. Protein Sci. 2005; 14: 1071-1081Crossref PubMed Scopus (143) Google Scholar). The CXCL12/CXCR4 signaling axis is critically involved in a wide variety of physiological functions. These include margination of neutrophils into the site of infection (9White F.A. Bhangoo S.K. Miller R.J. Nat. Rev. Drug Discov. 2005; 4: 834-844Crossref PubMed Scopus (215) Google Scholar, 10Kucia M. Jankowski K. Reca R. Wysoczynski M. Bandura L. Allendorf D.J. Zhang J. Ratajczak J. Ratajczak M.Z. J. Mol. Histol. 2004; 35: 233-245Crossref PubMed Scopus (589) Google Scholar), embryonic development (11Nagasawa T. Tachibana K. Kishimoto T. Semin. Immunol. 1998; 10: 179-185Crossref PubMed Scopus (204) Google Scholar), mobilization and directed migration of stem cells (12Kucia M. Reca R. Miekus K. Wanzeck J. Wojakowski W. Janowska-Wieczorek A. Ratajczak J. Ratajczak M.Z. Stem Cells (Durham). 2005; 23: 879-894Crossref PubMed Scopus (659) Google Scholar, 13Kucia M. Ratajczak J. Ratajczak M.Z. Biol. Cell. 2005; 97: 133-146Crossref PubMed Scopus (140) Google Scholar), and neurological function (14Bajetto A. Bonavia R. Barbero S. Florio T. Schettini G. Front. Neuroendocrinol. 2001; 22: 147-184Crossref PubMed Scopus (326) Google Scholar). CXCR4 is involved in HIV-1 infection and HIV-associated dementia (15Zhou N. Luo Z. Luo J. Liu D. Hall J.W. Pomerantz R.J. Huang Z. J. Biol. Chem. 2001; 276: 42826-42833Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 16Kaul M. Lipton S.A. Curr. HIV Res. 2006; 4: 307-318Crossref PubMed Scopus (138) Google Scholar), is implicated in cancer metastasis (17Muller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Barrera J.L. Mohar A. Verastegui E. Zlotnik A. Nature. 2001; 410: 50-56Crossref PubMed Scopus (4387) Google Scholar, 18Luker K.E. Luker G.D. Cancer Lett. 2006; 238: 30-41Crossref PubMed Scopus (229) Google Scholar, 19Epstein R.J. Nat. Rev. Cancer. 2004; 4: 901-909Crossref PubMed Scopus (116) Google Scholar), and genetic mutants are responsible for WHIM disease (20Diaz G.A. Gulino A.V. Curr. Allergy Asthma Rep. 2005; 5: 350-355Crossref PubMed Scopus (46) Google Scholar). There is mounting evidence that glycosaminoglycans modulate the activity of chemokines via direct interactions (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar). Although the complete functionality of these interactions is not yet completely understood, it is believed that GAGs and proteoglycans sequester chemokines (22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar). This sequestering increases dimerization and local concentrations, in turn leading to the formation of a chemokine gradient (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar, 22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar, 23Johnson Z. Proudfoot A.E. Handel T.M. Cytokine Growth Factor Rev. 2005; 16: 625-636Crossref PubMed Scopus (196) Google Scholar). In addition, heparan sulfate presents CXCL12 to CXCR4-expressing leukocytes (22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar). Another important functional aspect of heparin binding to CXCL12 is protection from proteolysis by dipeptidyl peptidase IV (CD26), which removes the NH2-terminal two residues thus inactivating CXCL12 (24Sadir R. Imberty A. Baleux F. Lortat-Jacob H. J. Biol. Chem. 2004; 279: 43854-43860Abstract Full Text Full Text PDF PubMed Scopus (169) Google Scholar). CXCL12 was originally shown to possess affinity for heparin and heparan sulfate by binding to heparin affinity resin (25Bleul C.C. Fuhlbrigge R.C. Casasnovas J.M. Aiuti A. Springer T.A. J. Exp. Med. 1996; 184: 1101-1109Crossref PubMed Scopus (1261) Google Scholar). It was proposed that positively charged CXCL12 and other chemokines interact with negatively charged GAGs through non-specific electrostatic interactions. However, this interaction was subsequently shown to be specific (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). CXCL12 bound independently of its receptor to CXCR4-negative cells through interaction with cell surface glycosaminoglycans. Amara et al. (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar) proceeded to use site-directed mutagenesis of CXCL12 to identify a BBXB motif on the first β-strand (Lys24, His25, and Lys27) that was critical for this in vitro interaction. This triple mutant retained its in vitro biological activity of stimulating intracellular calcium mobilization. However, the mutated CXCL12 had significantly decreased affinity for heparin (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). Interestingly, mutants of the CC chemokines CCL2 (MCP-1), CCL4 (MIP-1β), and CCL5 (RANTES) devoid of heparin binding retain in vitro chemotactic activity but lose in vivo activity (27Proudfoot A.E. Handel T.M. Johnson Z. Lau E.K. LiWang P. Clark-Lewis I. Borlat F. Wells T.N. Kosco-Vilbois M.H. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 1885-1890Crossref PubMed Scopus (627) Google Scholar). A model of the CXCL12-heparin complex was based on the mutagenesis studies (28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar). Sadir et al. (28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar) calculated an electrostatic potential map of CXCL12 and docked a heparin tetradecasaccharide into the positively charged groove. Energy minimization produced a structure in which heparin was modeled to bind quite well in the putative binding site between the subunits of the CXCL12 dimer. In the proposed model, heparin interacted primarily with the basic residues Lys1, Lys24, His25, Lys27, Arg41, and Lys43 and secondarily with Asn46 and Gln48. We determined that heparan sulfate as well as high and low molecular weight heparins have a concentration-dependent negative effect on CXCL12 driven chemotaxis of CXCR4+ CEM-CCRF cells. Our mutational data revealed a cluster of negatively charged residues involved in both chemotaxis and heparin binding. To elucidate the interactions between the proposed residues and heparin, we used NMR spectroscopy to monitor backbone chemical shift perturbations of CXCL12 during a titration with a heparin disaccharide. By using the fully sulfated, unsaturated disaccharide (heparin disaccharide I-S) derived from a fully sulfated heparin (Fig. 1B), we were able to use the minimum size that contains the basic structural elements required for CXCL12 binding. One chemical difference to be noted between this disaccharide and a typical heparin oligomer is the presence of a double bond between C4 and C5 of the uronic acid, making the disaccharide non-physiological. However, the relative positions of the sulfate moieties should remain unchanged. Therefore we used this disaccharide as a model for CXCL12-heparin interactions. The addition of the disaccharide affected two clusters of amino acids in a dose-dependent manner in NMR spectroscopy experiments. We then used x-ray crystallography to define the exact binding position of the disaccharides. The results from NMR spectroscopy combined with the crystal structure of CXCL12 in complex with the disaccharides define specific molecular interactions between CXCL12 and heparin. Our results not only support previous findings that heparin binds to basic residues in the dimer interface (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar, 28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar) but also identify an additional binding site. Reagents—Luria-Bertani medium, ampicillin, isopropyl 1-thio-β-d-galactopyranoside, Triton X-100, and dithiothreitol were purchased from American Bioanalytical (Natick, MA). 15N-ammonium chloride (98% 15N), heparin disaccharide I-S (containing an unsaturated hexauronate), oxidized and reduced glutathione, protease inhibitor mixture, ammonium sulfate, Trizma base (Tris base), and deuterium oxide were purchased from Sigma. CXCL12 Expression, Folding, and Purification—The gene encoding human CXCL12 was cloned into the NdeI and XhoI restriction sites of the pET-22b expression vector (Novagen®). The resulting plasmid was transformed into Escherichia coli BL21(DE3). 1.5 liters of Luria-Bertani media containing 100 μg/ml ampicillin were inoculated and grown to A600 of 0.6 and then induced with 1.0 mm isopropyl 1-thio-β-d-galactopyranoside. Induced cultures were grown for an additional4hat 37 °C and harvested by centrifugation for 10 min at 5000 × g. Cells were resuspended in 1× phosphate-buffered saline (pH 7.4) with 1% Triton X-100, lysed using a French Press and centrifuged for 20 min at 30,000 × g. CXCL12 was found exclusively in inclusion bodies. The inclusion bodies were washed three times in wash buffer A (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 5 mm dithiothreitol, 2 m urea, 2% Triton X-100) and once with wash buffer B (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 5mm dithiothreitol). Washed inclusion bodies were solubilized in 6 m guanidine HCl and diluted 1:100 into a refolding buffer (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 0.2 mm oxidized glutathione, 1 mm reduced glutathione) and stirred at 4 °C overnight. Precipitated material was removed by filtration. Refolded protein was bound to a SP-Sepharose column and eluted with a NaCl gradient. Fractions containing CXCL12 were pooled and were further purified by reverse phase-HPLC. The peak containing CXCL12 was concentrated and lyophilized. CXCL12 was resuspended in sterile ddH2O (pH 7.0) with 0.1 mm NaN3 and protease inhibitor mixture prior to use. Protein concentration was determined by direct amino acid analysis at the W. M. Keck facility (Yale University). 15N-Labeled CXCL12—Isotopically labeled 15N-CXCL12 was produced similar to native protein with the exception of the substitution of LB medium with M9 minimal media containing 1.0 g/liters of 15NH4Cl (98% 15N). Expression and Purification of Mutant CXCL12—For the chemotaxis assays, wild-type and mutant CXCL12 were expressed in HEK-293 cells to ensure proper folding using a mammalian expression vector containing a secretion signal sequence and an Fc tag at the carboxyl terminus of CXCL12 (kind gift of Timothy Springer of Harvard University). Mutagenesis of the plasmid was accomplished using the QuikChange and Multi-site QuikChange procedures (Stratagene). The proper sequence of all mutated plasmids was verified by DNA sequencing at the W. M. Keck facility (Yale University). HEK-293 cells were transformed at partial confluence by the calcium phosphate transfection method. After 24 h, the growth media containing secreted CXCL12-Fc was collected and treated with iodoacetamide to prevent aggregation. CXCL12-Fc was purified using protein A-Sepharose affinity chromatography. Cell Culture and Chemotaxis Assays—The CCRF-CEM acute lymphoblastic leukemia cell line (29Foley G.E. Lazarus H. Farber S. Uzman B.G. Boone B.A. Mc-Carthy R.E. Cancer. 1965; 18: 522-529Crossref PubMed Scopus (985) Google Scholar) was obtained from the American Type Culture Collection (CCL-119) and maintained as recommended by the ATCC. Chemotaxis assays were performed as previously described (30Sachpatzidis A. Benton B.K. Manfredi J.P. Wang H. Hamilton A. Dohlman H.G. Lolis E. J. Biol. Chem. 2003; 278: 896-907Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar). Briefly, semi-confluent cells were harvested and resuspended to ∼1 × 107 cells/ml. 100-μl Aliquots of cells were then placed in the upper chamber of a transwell (Corning-Costar®) with 5 μm pore size. Varying concentrations of CXCL12, heparin, and heparan sulfate are in the lower chamber. Following a 2-h incubation at 37 °C, cells which migrated to the lower chamber were counted with an electronic particle counter (Coulter®). NMR Spectroscopy—Samples for NMR spectroscopy contained 2 mm 15N-CXCL12, 10 mm HEPES, pH 7.4, and 5% D2O with variable concentrations of heparin disaccharide I-S (0-12 mm). Experiments were carried out at 35 °C in a Varian INOVA 600 MHz spectrometer with a 5-mm triple resonance probe equipped with triple-axis (XYZ) pulsed magnetic field gradients. All pulse sequences were taken from the Varian BioPack user library. Spectra were processed and analyzed using the programs nmrPipe (31Delaglio F. Grzesiek S. Vuister G.W. Zhu G. Pfeifer J. Bax A. J. Biomol. NMR. 1995; 6: 277-293Crossref PubMed Scopus (11280) Google Scholar) and Sparky. 4T. D. Goddard and D. G. Kneller, personal communication. Assignment of resonance peaks was done using three-dimensional 15N-TOCSY HSQC and 15N-NOESY HSQC NMR spectra of CXCL12 alone and previously published resonance assignments (33Gozansky E.K. Louis J.M. Caffrey M. Clore G.M. J. Mol. Biol. 2005; 345: 651-658Crossref PubMed Scopus (54) Google Scholar). Crystallography—CXCL12 was concentrated to 12 mg/ml in water. Protein crystals were grown using the hanging drop method in the previously published condition (2 m ammonium sulfate, 0.1 m Tris·HCl, pH 8.5) at 18 °C (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar). The crystals were soaked into 4-μl drops of heparin disaccharide I-S (16 mm) in 20% PEG-8000, 0.1 m Tris·HCl (pH 8.5) and incubated overnight at 18 °C. The crystals were protected in 20% PEG-8000, 0.1 m Tris·HCl (pH 8.5), and 25% glycerol for 1 min and frozen at -180 °C during data collection. Data Collection and Processing—X-ray diffraction data were collected on an R-axis IV detector (Rigaku) at the macromolecular crystallography facility at the Yale University School of Medicine. Data were processed using MOSFLM (34Leslie A.G. Acta Crystallogr. D Biol. Crystallogr. 1999; 55: 1696-1702Crossref PubMed Scopus (485) Google Scholar) and SCALA (35Four Collaborative Computational Project Number Acta Crystallogr. D Biol. Crystallogr. 1994; 50: 760-763Crossref PubMed Scopus (19668) Google Scholar). Phaser (36McCoy A.J. Grosse-Kunstleve R.W. Storoni L.C. Read R.J. Acta Crystallogr. D Biol. Crystallogr. 2005; 61: 458-464Crossref PubMed Scopus (1590) Google Scholar) was used for molecular replacement. The CCP4i software suite (37Potterton E. Briggs P. Turkenburg M. Dodson E. Acta Crystallogr. D Biol. Crystallogr. 2003; 59: 1131-1137Crossref PubMed Scopus (1042) Google Scholar) and the Crystallography and NMR (CNS) (38Brunger A.T. Adams P.D. Clore G.M. DeLano W.L. Gros P. Grosse-Kunstleve R.W. Jiang J.S. Kuszewski J. Nilges M. Pannu N.S. Read R.J. Rice L.M. Simonson T. Warren G.L. Acta Crystallogr. D Biol. Crystallogr. 1998; 54: 905-921Crossref PubMed Scopus (16919) Google Scholar) program suite were used for refinement and structure validation. Initial coordinates and structural libraries of the heparin disaccharide were created using the Dundee PRODRG server (39Schuttelkopf A.W. van Aalten D.M. Acta Crystallogr. D Biol. Crystallogr. 2004; 60: 1355-1363Crossref PubMed Scopus (4063) Google Scholar). Mutagenesis of Wild-type CXCL12-Fc Affects Chemotaxis and Inhibition of Chemotaxis by GAGs—Recombinant, refolded CXCL12 produced in E. coli and Fc-tagged CXCL12 produced in HEK-293 cells had equivalent chemotactic activity (data not shown). A series of mutants of CXCL12 were designed to probe the effect of various surface areas in CXCR4 binding and activation (Fig. 1A). The EC50 values and efficacies of these mutants as compared with the wild-type protein are in Table 1. The chemotactic index is a measure of the chemotactic activity of each protein, defined as the ratio of the number of cells migrated for each protein concentration to the number of cells migrated in response to assay media without chemokine. Efficacy (%) as used in Table 1 is a measure of the maximum activity of each mutant relative to the maximum chemotaxis of the wild type CXCL12.TABLE 1Effect of CXCL12 mutations on chemotaxisMutantEC50aEC50 was defined as the concentration of CXCL12 that gave 50% of the maximum response as determined by a concentration-response curve for each mutant.EfficacybEfficacy was calculated as the ratio of the maximum response of each mutant to the maximum response of wild-type CXCL12 multiplied by 100.nM%Wild-type7.9100R8Q/R12Q960110R8Q490100R12Q3592F13A/F14A2187E15Q/H17N13110T31G/A33G/A35G1881H25N/K27Q/R41Q/R47Q/Q48N4.166a EC50 was defined as the concentration of CXCL12 that gave 50% of the maximum response as determined by a concentration-response curve for each mutant.b Efficacy was calculated as the ratio of the maximum response of each mutant to the maximum response of wild-type CXCL12 multiplied by 100. Open table in a new tab The RFFESH motif (residues 12-17) was shown by others to have a role in receptor binding and activation through the use of chimeric chemokines with CXCL12 sequences, receptor binding assays, and intracellular calcium release upon agonist activation (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar). We further explored this region with the single mutant R12Q and two double mutants, F13A/F14A and E15Q/H17N. Our results show increases in EC50 values ranging from 1.6 to 4.4-fold for the three mutants relative to wild-type CXCL12. Although our results cannot be directly compared with those of Crump et al. (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar) due to differences in assays (chemotaxis versus Ca2+ mobilization), we agree that this region is important for CXCL12 function, with no particular residue making a large contribution relative to others. We were surprised, however, by the effect of Arg8 on the EC50. The maximum activity of three mutants R8Q, R12Q, and R8Q/R12Q is similar to wild type, but these mutants have correspondingly 60, 4, and 120 times higher EC50 values than the wild type. The positive charge of Arg8 is critical for activating CXCR4-mediated chemotaxis. A series of other mutants were designed to address the role of positively charged surface areas identified originally in the CXCL12 crystal structure (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar). One of these, a quintuple mutant H25N/K27Q/R41Q/R47Q/Q48N that removed the charges showed a 35% reduction in efficacy with respect to wild type but a similar EC50 suggesting that the loss of a large surface area of positive potential has a moderate effect on receptor activation. Alternatively, because this mutant showed a clear resistance to heparin inhibition (see below), its reduced activity may be due to a lack of interaction with native GAGs essential for a maximum chemotactic effect. A triple mutant comprising residues T31V/A33G/A35G showed a small reduction of EC50 and efficacy suggesting a possible role of these residues in CXCL12-CXCR4 interaction. Effect of GAGs on CXCL12-mediated Chemotaxis—As shown in Fig. 2, A and B, both heparan sulfate and high and low molecular weight heparin caused a clear reduction of the chemotactic activity of CXCL12 in all CXCL12 and GAG concentrations tested. The effect was significant at 10 or 100 μg/ml of GAG for both 10 and 100 nm CXCL12. These data are in agreement with previous observations on the negative regulatory effects of soluble GAGs on in vitro binding of CXCL12 to various cell lines (40Mbemba E. Benjouad A. Saffar L. Gattegno L. Virology. 1999; 265: 354-364Crossref PubMed Scopus (21) Google Scholar, 41Mbemba E. Gluckman J.C. Gattegno L. Glycobiology. 2000; 10: 21-29Crossref PubMed Google Scholar) and are consistent with a sequestration mechanism that prevents the interaction of the chemokine with the cell surface. It is important to clarify that these data do not preclude the positive regulatory role of native GAGs on CXCL12 activity and proper presentation to its receptor CXCR4. In fact, treatment of cells with enzymes known to degrade GAGs (heparitinases) induces a significant reduction of CXCL12 binding to cells (40Mbemba E. Benjouad A. Saffar L. Gattegno L. Virology. 1999; 265: 354-364Crossref PubMed Scopus (21) Google Scholar, 41Mbemba E. Gluckman J.C. Gattegno L. Glycobiology. 2000; 10: 21-29Crossref PubMed Google Scholar) indicating an important role of native membrane-bound GAGs in binding CXCL12 and increasing its local availability for interaction with CXCR4. It is also noteworthy that soluble GAGs have similar inhibitory effects on the activities of most other chemokines tested up to now (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar, 22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar, 23Johnson Z. Proudfoot A.E. Handel T.M. Cytokine Growth Factor Rev. 2005; 16: 625-636Crossref PubMed Scopus (196) Google Scholar) with the exception of the positive effect of heparan sulfate on neutrophil responses to CXCL8 (interleukin-8) (42Webb L.M. Ehrengruber M.U. Clark-Lewis I. Baggiolini M. Rot A. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 7158-7162Crossref PubMed Scopus (408) Google Scholar). It is likely that the soluble heparins that inhibit chemotaxis either do not form a receptor-activating complex with the chemokine or compete with the membrane-bound glycosaminoglycans on the cell that would result in an activated complex. Effect of Heparin on the Activity of CXCL12 Mutants—Most CXCL12 mutants tested showed significant heparin-induced inhibition of their chemotactic activity (Fig. 3). The F13A/F14A and E15Q/H17N double mutants and the T31V/A33G/A35G triple mutant showed a level of inhibition comparable with that of the wild-type protein indicating that the GAG-chemokine interaction was not significantly modified in these mutants. On the contrary, the H25N/K27Q/R41Q/R47Q/Q48N quintuple mutant showed a clear resistance to inhibition by heparin indicating that the GAG-CXCL12 interaction has been significantly disrupted. Four positive charges are neutralized in this mutant and the data support the suggestion that some or all of these residues, His25, Lys27, Arg41, Arg47 (and Gln48), are somehow involved in GAG binding. This is in agreement with previous mutagenesis studies (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). The most unexpected observation from this series of experiments came from the effect of heparin on the R8Q and R12Q single mutants. In both of these cases, the mutants showed a remarkable hypersensitivity to heparin with more than 80% of the activity lost upon binding a GAG vers

The Role of CD47 in Neutrophil Transmigration

Soluble CD40 Ligand Stimulates CD40-Dependent Activation of the Β2 Integrin Mac-1 and Protein Kinase C Zeda (pkcζ) in Neutrophils: Implications for Neutrophil-Platelet Interactions and Neutrophil Oxidative Burst

CD47 (Cluster of Differentiation 47)

CD11B/CD18 SIALYLATION REGULATES NEUTROPHIL TRAFFICKING AND INFLAMMATORY FUNCTION IN THE INTESTINE

The Heparan Sulfate Proteoglycan Form of Epithelial CD44v3 Serves as a CD11b/CD18 Counter-receptor during Polymorphonuclear Leukocyte Transepithelial Migration

Structural and Functional Basis of CXCL12 (stromal Cell-derived Factor-1α) Binding to Heparin

Cleavage of the CD11b Extracellular Domain by the Leukocyte Serprocidins is Critical for Neutrophil Detachment During Chemotaxis (173.7)

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Epithelial exposure to hypoxia modulates neutrophil transepithelial migration

Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity

Released Myeloperoxidase Attenuates Neutrophil Migration and Accumulation in Inflamed Tissue

How Adhesion Molecule Patterns Change While Neutrophils Traffic through the Lung during Inflammation

Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa

Neutrophils exhibit distinct migration phenotypes that are regulated by transendothelial migration

Structural–functional diversity of CD47 proteoforms

Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment

Sialylation regulates neutrophil transepithelial migration, CD11b/CD18 activation, and intestinal mucosal inflammatory function

Tolerating CD47

Mechanistic Insights into Macrophages Regulation of Neutrophil Transendothelial Migration in Inflamed Mucosa

CD31 signaling promotes the detachment at the uropod of extravasating neutrophils allowing their migration to sites of inflammation

Human CD99L2 Regulates a Unique Step in Leukocyte Transmigration